SCHEMBL649475

SCHEMBL649475

CCOC(=O)c1cnc(N2CCC(CN)CC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 1/20 0.47
ACACB O00763 1/20 0.44
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
PTPN11 Q06124 1/20 0.40
PIK3CA P42336 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
KDM1A O60341 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
P2RY12 Q9H244 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
HDAC1 Q13547 1/20 0.39
EHMT2 Q96KQ7 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
FDFT1 P37268 1/20 0.38
OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2622717 0.88 OGA (0.47) OGAACACBPOLBMAPTHRH3
SCHEMBL753762 0.87 OGA (0.48) OGAACACBPOLBMAPTHRH3
SCHEMBL9883418 0.87 OGA (0.45) OGAMAPTPIK3CAGPR119KDM1A
SCHEMBL20046331 0.86 OGA (0.46) OGAACACBPOLBMAPTHRH3
Hydrochloric Acid SCHEMBL21615911 0.86 OGA (0.44) OGAMAPTPIK3CAGPR119KDM1A
SCHEMBL4211279 0.85 OGA (0.49) OGAACACBPOLBMAPTHRH3
SCHEMBL15994455 0.85 OGA (0.49) OGAACACBPOLBMAPTHRH3
SCHEMBL10194552 0.85 ACACB (0.45) OGAACACBPOLBMAPTHRH3
SCHEMBL15994451 0.84 OGA (0.48) OGAACACBPOLBMAPTHRH3
SCHEMBL25141686 0.84 POLB (0.45) OGAACACBPOLBMAPTHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety CURIS INC (US) 2025-07-17 US disclosed
US-20230227467-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2023-07-20 US disclosed
US-20230227467-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2023-07-20 US disclosed
US-20230227467-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2023-07-20 US disclosed
US-11597732-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2023-03-07 US disclosed
US-20220402934-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2022-12-22 US disclosed
US-20220402934-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2022-12-22 US disclosed
US-11261195-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2022-03-01 US disclosed
US-20210214370-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2021-07-15 US disclosed
US-20210214370-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2021-07-15 US disclosed
US-7501417-B2 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control JANSSEN PHARMACEUTICA, N.V. (BE) 2009-03-10 US disclosed
CN-101374828-A Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2009-02-25 CN disclosed
CN-101370804-A Novel aminophenyl derivatives as histone deacetylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-02-18 CN disclosed
CN-101370803-A Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2009-02-18 CN disclosed
US-20090018152-A1 Aminophenyl Derivatives as Novel Inhibitors of Histone Deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-15 US disclosed
EP-1981874-A1 AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE Janssen Pharmaceutica, N.V. (BE) 2008-10-22 EP disclosed
EP-1885710-A1 SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE Janssen Pharmaceutica, N.V. (BE) 2008-02-13 EP disclosed
WO-2007082878-A1 AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-26 WO disclosed
CN-1993353-A Substituted indolyl alkylamino derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2007-07-04 CN disclosed
WO-2006122926-A1 SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018152-A1 Aminophenyl Derivatives as Novel Inhibitors of Histone Deacetylase HDAC1, HDAC9, HDAC11 OGA 3193/4885ACACB 905/4885POLB 716/4885
US-11261195-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety BAZ2A, BAZ2B, PI4KB OGA 1683/4885ACACB 1629/4885POLB 978/4885
US-20210214370-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB OGA 1688/4885ACACB 1718/4885POLB 963/4885
US-11597732-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety BAZ2A, BAZ2B, PI4KB OGA 1688/4885ACACB 1718/4885POLB 963/4885
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety BAZ2A, BAZ2B, PI4KB OGA 1683/4885ACACB 1629/4885POLB 978/4885
US-20230227467-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB OGA 1683/4885ACACB 1629/4885POLB 978/4885
US-20220402934-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB OGA 1683/4885ACACB 1629/4885POLB 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.